Most Miss Streamlined Neck Mass Dx Path

• by Andrea Surnit

• June 19, 2026

Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC

• by Bernd Uhl, Dennis Eggert, Bojan Smiljanov, Katharina von Thun und Hohenstein, Christoph Walz, Gisela Kranz, Sabina Schwenk-Zieger, Florian Haring, Joshua Luft, Jiahang Song, Vincent Holtmann, Philipp Baumeister, Christoph A. Reichel, Olivier Gires, Martin Canis, Christian Betz

• May 25, 2026

Updated CAP Protocols Explained

• April 20, 2026

• 3 min

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

• by Andrea Surnit

• June 5, 2026

• 6 min